Modular Medical, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2024, compared with fiscal 2023. This is an annual report, not a filing for the calendar fourth quarter alone.
Business context and reporting period
Modular Medical is a pre-revenue medical-device company developing the MODD1, a two-part wearable insulin pump intended for people with type 1 and insulin-requiring type 2 diabetes. The company has no commercial product revenue and is focused on completing FDA review, preparing manufacturing, and pursuing commercialization.
MODD1’s proposed features include a reusable pump and three-day disposable cartridge, button-based dosing, and a 300-unit insulin capacity. The company submitted a 510(k) notification to the FDA in January 2024 and received FDA comments in March; responses were in progress at the filing date.
Financial results and liquidity
| Metric | FY2024 | FY2023 |
|---|---|---|
| Revenue | None; pre-revenue | None; pre-revenue |
| Research and development expense | $12.880 million | $9.062 million |
| General and administrative expense | $4.649 million | $4.816 million |
| Total operating expenses / operating loss | $17.529 million | $13.878 million |
| Net loss | $17.470 million | $13.879 million |
| Basic and diluted loss per share | $0.78 | $1.15 |
| Cash used in operating activities | $13.952 million | $11.011 million |
| Cash used in investing activities | $1.700 million | $1.638 million |
At March 31, 2024, cash and cash equivalents were $9.232 million, current assets were $9.697 million, and total assets were $13.807 million. Current liabilities were $1.455 million; total liabilities were $2.272 million, including $1.190 million of lease liabilities. The filing does not report conventional borrowings on the balance sheet. Accumulated deficit was $65.929 million. No gross profit or margin is reported because the company had no revenue.
Cash provided by financing activities was $21.085 million, principally from equity offerings. The February 2024 offering and over-allotment generated approximately $10.3 million net proceeds; the May 2023 offering generated approximately $9.7 million net proceeds. The company also reported $0.3 million of net ATM proceeds and warrant-exercise proceeds. It reported approximately $0.9 million of additional warrant-exercise proceeds from December 2023 through April 2024.
The company had 32.464 million common shares outstanding at year-end, versus 10.949 million a year earlier. It also had 12.521 million warrants outstanding at March 31, 2024, as well as options and restricted stock units, creating potential dilution.
Material changes versus the prior period
- R&D expense increased 42.1%, reflecting engineering and operations staffing, consultants and outside testing for the FDA submission, materials, and depreciation.
- G&A expense decreased 3.5%, mainly due to lower stock-based compensation, consulting, and personnel costs, partly offset by higher professional services, facilities, and marketing expenses.
- Net loss increased to $17.470 million from $13.879 million, while reported loss per share declined to $0.78 from $1.15, reflecting a larger weighted-average share count.
- Property and equipment increased to $2.975 million from $1.721 million, as the company invested in manufacturing equipment and production preparation.
- The company completed substantial equity financing, but its share count nearly tripled during the year.
Outlook, commentary, risks, and unusual items
- Going concern: Management and the auditor stated that substantial doubt exists about the company’s ability to continue as a going concern for at least 12 months after issuance of the financial statements. The company says it needs additional capital; availability and terms are uncertain. The audited statements were prepared on a going-concern basis and include no adjustments for a possible failure to continue operations.
- Spending outlook: Management expects R&D and G&A expenses to rise in fiscal 2025 as it responds to FDA comments, hires personnel, transfers and validates manufacturing, and prepares for commercialization. The company described a planned full launch in early 2025 following a post-clearance soft launch; timing depends on FDA clearance and execution.
- Regulatory and commercialization risk: FDA clearance remains pending. The company must also validate production at Phillips-Medisize, secure adequate reimbursement and payor coverage, and gain acceptance among clinicians and patients. European and UK approvals were targeted for around mid-2025.
- Manufacturing and supply risks: The company relies on third parties for manufacturing and components, reports prior delays obtaining integrated circuits, and has no supply agreements with its suppliers. It has approximately $1.1 million of outstanding machinery and equipment purchase orders.
- Other commitments and unusual items: A device-integration agreement carried approximately $400,000 of remaining technology-license fees over three years. A royalty agreement with the founder provides for future product-sale royalties of the lesser of $0.75 per unit or 5% of gross sale price, capped at $10 million in total payments.
- The company reported no material legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective as of March 31, 2024; the auditor did not provide an internal-control audit opinion.
Important facts for investors to verify
- Current FDA review status, outstanding information requests, and realistic timing for 510(k) clearance.
- Cash runway, required financing, and potential dilution from future equity or warrant exercises.
- Manufacturing transfer, validation, capacity, product quality, and component-supply readiness.
- Evidence of payor coverage, reimbursement terms, clinician adoption, and patient demand at launch.
- Clinical and usability evidence supporting product safety, performance, and the company’s market and cost claims.
- Potential share dilution from outstanding warrants, options, restricted stock units, and future compensation awards.